Biopsies from the same patients before and after treatment reveal how a specific drug reprograms prostate tumors.

The findings could help shorten hospital stays for cancer patients.

By raising awareness about the correlation between increased radiation exposure and cardiac events, average doses were reduced without minimizing cancer treatment. 

Findings suggest this method could provide data about tumors sooner than MRIs alone.

The trial advances basic science research on the relationship between purine levels and treatment resistance to develop new treatment options for patients.

The anti-cancer effect of the drug may help those with rare, hereditary cancer syndromes avoid surgeries by shrinking tumors via a daily oral dose.